background
grow
evid
exist
solubl
angiotensin
convert
biomark
definit
heart
failur
hf
littl
inform
chang
activ
hypertens
immin
heart
failur
revers
remodel
method
find
patient
systol
hf
nyhaiiiv
enrol
cardiac
resynchronis
therapi
crt
n
compar
hypertens
patient
n
healthi
cohort
n
preserv
eject
fraction
singl
center
prospect
clinic
studi
statu
heart
failur
patient
check
crt
biochem
ace
activ
ace
concentr
echocardiograph
paramet
ef
left
ventricular
enddiastol
edd
endsystol
diamet
esd
dpdt
measur
activ
neg
correl
ef
posit
esd
edd
patient
popul
independ
healthi
cohort
activ
alreadi
increas
hypertens
group
sign
immin
heart
failur
slightli
decreas
ef
bare
increas
ntprobnp
level
detect
activ
increas
patient
definit
heart
failur
ef
activ
decreas
improv
heart
failur
crt
revers
remodel
serum
angiotensin
convert
enzym
ace
concentr
lower
diseas
popul
show
strong
correl
echocardiograph
paramet
conclus
solubl
activ
appear
biomark
heart
failur
hypertens
heart
failur
may
immin
data
suggest
involv
pathomechan
hypertens
hf
citat
ri
k
fagya
siket
z
et
al
new
perspect
reninangiotensinaldosteron
system
raa
iv
circul
biomark
systol
dysfunct
human
hypertens
heart
failur
plo
one
reninangiotensin
system
ra
central
regul
cardiovascular
renal
function
play
import
role
pathophysiolog
heart
failur
solubl
angiotensin
convert
enzym
recent
discov
homologu
ace
monocarboxypeptidas
gener
ang
angi
ang
angii
ang
biolog
activ
metabolit
ra
act
gproteincoupl
ma
receptor
ang
capabl
reduc
myocardi
oxid
stress
patholog
remodel
ma
receptor
heterooligomer
act
physiolog
antagonist
angii
heart
express
variou
cell
type
includ
fibroblast
cardiomyocyt
endotheli
cell
although
plasma
membranebound
ectoenzym
solubl
activ
form
protein
also
found
plasma
urin
tumor
necrosi
factor
alpha
convert
enzym
sheddas
respons
ectodomain
cleavag
shed
opposit
pathway
may
provid
vasoprotectiveantiprolif
mechan
result
counterregul
ra
accord
previou
anim
data
shown
transgen
overexpress
attenu
hypertens
suppress
express
establish
neg
regul
ra
blood
pressur
control
moreov
polymorph
relat
hypertens
differ
human
popul
nonetheless
express
activ
human
hypertens
address
directli
yet
contrast
hypertens
alreadi
studi
anim
human
hf
suggest
protect
role
enzym
target
disrupt
mice
result
sever
cardiac
contractil
defect
increas
plasma
heart
angii
level
lead
cardiac
dysfunct
absenc
caus
stress
activ
myocardi
nadph
oxidas
system
lead
sever
advers
myocardi
remodel
dysfunct
suggest
myocardi
gene
express
increas
patient
left
ventricular
dysfunct
tace
also
upregul
hf
loss
worsen
patholog
remodel
result
rapid
progress
systol
dysfunct
hf
epelman
et
al
show
increas
activ
associ
advanc
hf
elev
activ
could
predict
advers
cardiac
event
lehmann
et
al
recent
observ
higher
activ
hfpatient
experienc
ventricular
arrhythmia
appropri
defibrillatorintervent
whether
consider
correl
make
activ
suitabl
novel
biomark
heart
failur
still
settl
grow
evid
exist
irrefut
import
pathophysiolog
hf
howev
littl
inform
chang
activ
progress
diseas
well
revers
chang
medic
therapi
cardiac
resynchron
therapi
crt
report
singl
center
prospect
clinic
studi
establish
relationship
circul
ace
clinic
paramet
hypertens
cardiac
perform
consid
use
term
relat
ace
enzymeact
enzymelevel
occur
inconsist
literatur
perform
parallel
ace
enzym
activ
enzym
concentr
measur
studi
relationship
patient
sever
remodel
revers
remodel
improv
systol
function
achiev
biventricular
pacemak
devic
therapi
activ
measur
hypertens
patient
first
time
identifi
biomark
immin
heart
failur
cardiac
eject
fraction
deterior
cardiac
perform
expect
eg
patient
hypertens
written
inform
consent
obtain
patient
clinic
investig
conduct
accord
principl
express
declar
helsinki
studi
approv
region
institut
ethic
committe
medic
health
scienc
center
univers
debrecen
udmhsc
reciec
number
medic
research
council
hungari
singl
center
prospect
clinic
studi
perform
institut
cardiolog
univers
debrecen
investig
relationship
serum
activ
cardiovascular
patholog
among
paramet
three
studi
group
healthi
individu
n
without
cardiovascular
patholog
medic
recruit
normal
cardiac
morpholog
left
ventricular
eject
fraction
second
group
hypertens
patient
systol
blood
pressur
mmhg
andor
diastol
blood
pressur
mmhg
time
diagnosi
diseas
establish
group
character
preserv
eject
fraction
besid
optim
antihypertens
therapi
accord
nation
guidelin
tabl
third
group
patient
sever
left
ventricular
systol
dysfunct
indic
cardiac
resynchron
therapi
heart
failur
hf
also
enrol
studi
hf
crt
patient
select
crt
accord
current
esc
guidelin
relat
pharmaceut
devic
therapi
systol
heart
failur
till
date
patient
fulfil
first
visit
month
hf
crt
statist
analys
diagram
contain
exclus
data
signific
mitral
regurgit
present
patient
enabl
dpdt
measur
examin
perform
enrol
healthi
group
regular
visit
hypertens
group
hf
crt
group
month
crt
devic
implant
hf
crt
group
visit
includ
physic
examin
assess
new
york
heart
associ
nyha
function
stage
echocardiograph
measur
blood
sampl
collect
biochem
measur
cardiovascular
risk
assess
compris
age
sex
hypertens
hypercholesterinaemia
diabet
mellitu
ischaem
cardiomyopathi
tabl
nyha
classif
perform
independ
clinician
awar
echocardiograph
data
medic
report
medic
histori
obtain
patient
transthorac
echocardiographi
perform
use
accuson
sequoia
siemen
ag
germani
echocardiograph
two
dimension
doppler
imag
perform
standard
parastern
apic
view
left
ventricular
eject
fraction
ef
measur
mode
left
ventricular
dimension
method
preserv
ef
cutoff
valu
dpdt
function
paramet
relat
left
ventricular
contractil
determin
patient
sever
mitral
regurgit
two
experienc
cardiologist
unawar
biochem
data
perform
echocardiograph
measur
blood
sampl
collect
use
standard
asept
techniqu
nativ
blood
incub
minut
room
temperatur
serum
fraction
separ
centrifug
g
min
kept
freezer
measur
activ
measur
perform
use
specif
quench
fluoresc
substrat
previous
describ
modif
reaction
mixtur
ml
contain
ml
serum
ml
buffer
ml
mm
fluoresc
substrat
acetylalaproli
oh
mcaapk
dnp
ez
biolab
carmel
usa
activ
measur
fluorometr
assay
enzymat
cleavag
k
dnp
fluorogen
substrat
mcaapk
dnp
reaction
buffer
contain
proteas
inhibitor
cocktail
mm
bestatinhidrochlorid
mm
zprolylprolin
enzo
life
scienc
exet
uk
mm
amastatinhidrochlorid
mm
captopril
mm
naci
mm
znci
mm
tri
hci
ph
chemic
sigma
st
loui
mo
usa
state
otherwis
reaction
perform
black
microtit
plate
greiner
bioon
frickenhaus
germani
assay
monitor
continu
measur
increas
fluoresc
excit
wavelength
nm
emiss
wavelength
nm
upon
substrat
hydrolysi
use
fluoresc
micropl
reader
novostar
bmg
labtech
gmbh
offenburg
germani
initi
enzym
activ
determin
linear
rate
fluoresc
increas
min
time
cours
increas
fluoresc
plot
function
reaction
time
fit
linear
regress
assess
ace
activ
base
spectrophotometr
measur
fapgg
hydrolysi
reaction
mixtur
ml
contain
ml
serum
mm
fapgg
n
loui
mo
usa
substrat
mm
sodium
chlorid
mm
hepe
acid
ph
measur
ace
activ
base
chang
absorpt
nm
fapgg
hydrolyz
furylacryloyllphenylalalin
fap
glycylglycin
gg
reaction
perform
plate
greiner
bioon
frickenhaus
germani
chang
fapgg
absorb
detect
use
micropl
reader
novostar
bmg
labtech
gmbh
offenburg
germani
hydrolysi
fapgg
ace
record
everi
minut
optic
densiti
valu
plot
function
reaction
time
fit
linear
regress
fit
data
accept
ace
activ
calcul
equat
ace
activ
sk
rate
observ
decreas
optic
densiti
min
k
chang
optic
densiti
upon
complet
cleavag
nmol
fapgg
dilut
serum
one
unit
u
ace
activ
repres
nmol
fapgg
hydrolysi
per
minut
uc
ace
concentr
determin
use
human
ace
enzymelink
immunosorb
assay
elisa
develop
system
catalog
r
system
inc
minneapoli
usa
accord
manufactur
instruct
minor
modif
brief
enzymelink
immunosorb
assay
plate
coat
captur
antibodi
dilut
work
concentr
ngwell
dulbecco
modifi
phosphatebuff
salin
solut
dpb
invitrogen
corp
carlsbad
ca
usa
overnight
room
temperatur
remain
bind
site
block
bovin
serum
albumin
sigma
st
loui
mo
usa
mgml
dissolv
dpb
human
serum
sampl
dilut
buffer
mgml
bovin
serum
albumin
dpb
incub
immobil
primari
antibodi
hour
captur
antibodybound
ace
label
use
biotinyl
detect
antibodi
ngwell
hour
streptavidinconjug
horseradishperoxidas
stock
kit
ad
well
incub
minut
immunocomplex
detect
chromogen
substrat
solut
contain
mgml
tmb
mm
h
mm
acet
acid
incub
time
minut
reaction
termin
addit
hcl
evalu
measur
absorb
nm
ace
concentr
calcul
use
calibr
curv
ace
concentr
sampl
measur
least
three
time
achiev
standard
deviat
serum
ace
concentr
given
ngml
serum
ntermin
probrain
natriuret
peptid
ntprobnp
measur
ntprobnp
level
measur
serum
use
commerci
avail
kit
elecsi
probnp
ii
roch
ltd
mannheim
germani
unpair
echocardiograph
valu
analyz
nonparametr
kruskalw
test
two
tail
figur
c
nonparametr
test
differ
hypertens
healthi
patient
group
bar
mean
sem
signific
differ
label
asterisk
p
pair
echocardiograph
data
crt
figur
evalu
nonparametr
wilcoxon
matchedpair
sign
rank
test
two
tail
dpdt
paramet
analyzi
pair
ttest
two
tail
figur
statist
differ
biochem
paramet
figur
solubl
activ
evalu
figur
address
parametr
anova
test
comparison
grouppair
newmankeul
post
test
linear
regress
analysi
perform
compar
activ
echocardiograph
paramet
ntprobnp
level
figur
linear
regress
analysi
perform
compar
serum
ace
concentr
echocardiograph
paramet
figur
consid
statist
signific
comparison
statist
analys
perform
use
commerci
avail
softwar
graphpad
prism
version
graphpad
softwar
inc
san
diego
ca
usa
clinic
characterist
studi
group
shown
tabl
healthi
systolicdiastol
blood
pressur
mmhg
hypertens
group
optim
medic
therapi
systolicdiastol
blood
pressur
mmhg
consist
individu
appar
symptom
clinic
sign
systol
diastol
heart
failur
tabl
crt
group
consist
patient
mild
nyha
ii
sever
heart
failur
nyha
iiiiv
match
ecg
echocardiograph
criteria
biventricular
pacemak
implant
mean
ef
crt
group
serious
reduc
tabl
enlarg
endsystol
esd
tabl
enddiastol
edd
tabl
diamet
case
crtd
devic
implant
significantli
elev
ntprobnp
level
found
hypertens
crt
group
compar
healthi
group
occurr
cardiovascular
risk
factor
medic
studi
popul
also
summar
tabl
pharmaceut
therapi
remain
unchang
studi
hypertens
heart
failur
hf
patient
significantli
enlarg
initi
left
ventricular
dimens
esd
edd
cardiac
resynchron
therapi
hf
crt
compar
healthi
individu
tabl
figur
sever
reduct
left
ventricular
pump
function
observ
repres
reduc
ef
crt
group
tabl
figur
signific
decreas
esd
edd
esd
mm
edd
mm
figur
found
follow
month
biventricular
pace
hf
crt
pump
function
also
improv
great
extent
group
ef
figur
dpdt
paramet
chang
signific
manner
well
follow
crt
mmhg
figur
activ
posit
correl
clinic
statu
systol
heart
failur
patient
remark
elev
activ
present
crt
patient
pacemak
implant
hf
crt
compar
healthi
peopl
hypertens
patient
preserv
left
ventricular
ef
healthi
ufml
hypertens
ufml
hf
crt
uf
ml
figur
serum
activ
strongli
correl
clinic
condit
patient
sever
heart
failur
hf
crt
nyhaii
ufml
nyhaiii
uf
ml
nyhaiv
ufml
figur
posit
correl
nyha
class
remain
unchang
pacemak
implant
hf
crt
nyhai
ufml
nyhaii
ufml
nyhaiii
ufml
figur
clinic
statu
improv
hfpatient
angiotensin
convert
enzym
ace
express
gener
lower
heart
failur
patient
crt
healthi
ngml
hypertens
ngml
hf
crt
nyha
ii
ngml
nyhaiii
ng
ml
nyhaiv
ngml
figur
gener
relationship
disappear
crt
hf
crt
nyhai
ngml
nyhaii
ngml
nyha
iii
ngml
figur
activ
correl
hypertens
deterior
left
ventricular
systol
function
serum
activ
correl
clinic
statu
hf
accordingli
perform
detail
studi
identifi
serum
biomark
human
heart
failur
serum
activ
plot
function
systol
eject
fraction
studi
group
figur
serum
activ
neg
correl
ef
hypertens
patient
figur
similarli
hf
patient
figur
contrast
correl
present
ef
activ
healthi
individu
figur
moreov
clear
posit
correl
found
serum
activ
esd
figur
edd
figur
hf
patient
activ
correl
improv
left
ventricular
function
serum
activ
higher
hypertens
patient
compar
healthi
individu
hypertens
ufml
healthi
ufml
figur
increas
hf
patient
hf
crt
ufml
figur
suggest
activ
may
biomark
cardiovascular
diseas
immin
heart
failur
respect
good
biomark
also
correl
clinic
improv
diseas
correl
therefor
also
investig
upon
clinic
improv
biventricular
pacemak
implant
hfcrt
robust
reduct
serum
activ
found
parallel
improv
cardiac
perform
function
call
revers
remodel
hf
crt
ufml
figur
regress
analys
serum
function
ef
crt
reveal
correl
remain
neg
r
figur
posit
correl
activ
esd
edd
also
preserv
esd
r
edd
p
r
figur
correl
activ
ntprobnp
individu
normal
left
ventricular
systol
function
healthi
hypertens
figur
serum
activ
posit
correl
ntprobnp
level
hf
patient
crt
hf
crt
r
figur
posit
correl
activ
ntprobnp
maintain
crt
hf
crt
r
figur
ace
activ
cardiovascular
patient
hypertens
uml
hf
crt
uml
hf
crt
uml
figur
significantli
lower
healthi
individu
healthi
uml
figur
probabl
repres
success
ace
inhibitori
therapi
patient
sever
systol
heart
failur
significantli
lower
enzym
concentr
patient
preserv
ef
healthi
ngml
hypertens
ngml
hf
crt
ngml
figur
moreov
serum
ace
concentr
increas
pacemak
implant
hf
crt
ngml
figur
nevertheless
regress
analys
ace
concentr
function
ef
crt
hf
crt
crt
hfcrt
show
signific
correl
figur
one
frequent
cardiovascular
diseas
hypertens
lead
secondari
cardiomyopathi
coronari
arteri
diseas
stroke
peripher
arteri
diseas
chronic
nephropathi
neuropathi
mani
sever
patholog
ultim
increas
mortal
interestingli
case
identifi
caus
essenti
hypertens
import
note
effect
treatment
hypertens
make
rel
easili
manag
diseas
cure
probabl
relat
issu
also
determin
respect
new
york
heart
associ
nyha
function
class
patient
hf
crt
panel
crt
hf
crt
panel
e
statist
analys
healthi
peopl
hypertens
hf
crt
hf
crt
group
perform
oneway
analysi
varianc
anova
follow
newmankeul
test
multipl
comparison
group
bar
mean
sem
signific
differ
label
asterisk
serum
activ
correl
revers
remodel
serum
activ
determin
healthi
peopl
healthi
n
fill
bar
patient
preserv
eject
fraction
hypertens
n
grey
bar
patient
sever
heart
failur
hf
crt
hf
crt
cardiac
resynchron
therapi
crt
n
open
bar
panel
statist
analys
perform
oneway
analysi
varianc
anova
follow
newmankeul
test
multipl
comparison
group
bar
repres
mean
sem
signific
differ
valu
label
asterisk
addit
individu
valu
patient
crt
hf
crt
also
shown
panel
caus
diseas
known
result
patient
treat
blood
pressur
kept
accept
level
target
blood
pressur
reach
medic
background
patholog
caus
hypertens
may
unaffect
found
first
time
serum
activ
increas
hypertens
patient
without
appar
heart
failur
eject
fraction
compar
healthi
individu
nonetheless
hypertens
patient
alreadi
bare
decreas
eject
fraction
compar
healthi
popul
also
featur
slightli
elev
ntprobnp
level
suggest
popul
immin
heart
failur
stage
diseas
serum
activ
alreadi
elev
although
correl
ntprobnp
level
appear
therefor
serum
activ
anoth
biomark
immin
heart
failur
hypertens
importantli
may
also
relat
caus
diseas
regul
decreas
local
angiotensin
bd
serum
activ
plot
function
eject
fraction
ef
panel
b
end
systol
diamet
esd
panel
c
end
diastol
diamet
edd
panel
plot
fit
linear
regress
good
fit
indic
r
valu
correl
repres
p
valu
ii
level
affect
vascular
diamet
vascular
smooth
muscl
locat
angiotensin
receptor
sympathet
tone
neuron
angiotensin
receptor
may
also
contribut
synthesi
angiotensin
peptid
may
activ
ma
receptor
believ
benefici
hypertens
hypothesi
support
recent
find
suggest
serum
ace
ratelimit
step
raa
endogen
inhibitor
serum
albumin
effect
inhibit
circul
ace
activ
human
although
first
time
increas
activ
shown
hypertens
human
potenti
connect
regul
blood
pressur
new
concept
previou
anim
data
shown
transgen
overexpress
vessel
shrsp
rat
normal
reduc
high
blood
pressur
modul
activ
nervou
system
overexpress
also
attenu
hypertens
indic
possibl
protect
role
hypertens
genet
inactiv
found
neg
regul
ra
blood
pressur
control
moreov
genet
associ
studi
shown
strong
associ
polymorph
hypertens
differ
human
popul
although
without
refer
actual
effect
polymorph
circul
activ
respect
studi
identifi
activ
biomark
immin
human
heart
failur
also
implic
biomark
definit
heart
failur
anim
model
absenc
caus
sever
impair
cardiac
function
wealth
inform
human
heart
failur
myocardi
gene
express
increas
patient
left
ventricular
dysfunct
includ
thin
left
ventricl
sever
reduct
cardiac
contractil
burrel
et
al
observ
increas
express
fail
human
heart
independ
blockad
loss
worsen
patholog
remodel
systol
dysfunct
moreov
gene
express
increas
tissu
sampl
patient
left
ventricular
dysfunct
serum
activ
elev
correl
diseas
sever
made
effort
directli
address
relationship
serum
activ
cardiac
function
chang
serum
activ
measur
sever
heart
failur
cardiac
resynchron
therapi
crt
indic
found
signific
relationship
among
plasma
activ
left
ventricular
eject
fraction
ef
ntprobnp
figur
report
earlier
epelman
et
al
new
data
therefor
repeat
find
howev
also
made
detail
analysi
relationship
serum
activ
echocardiograph
systol
paramet
ef
individu
patient
level
figur
serum
activ
neg
correl
ef
patient
systol
hf
figur
well
hypertens
patient
preserv
ef
figur
healthi
volunt
figur
hf
peopl
serum
activ
also
correl
ntprobnp
concentr
wide
use
molecular
marker
systol
hf
reason
high
predict
prognost
valu
suggest
solubl
level
independ
predictor
composit
endpoint
consist
allcaus
mortal
cardiac
transplant
heart
failur
hospit
first
time
shown
ntprobnp
concentr
posit
correl
serum
activ
individu
patient
level
figur
particular
observ
show
clearli
identifi
patient
popul
high
ntprobnp
rel
low
level
suggest
better
prognost
factor
furthermor
kind
relationship
still
exist
cardiac
function
improv
figur
elev
circul
level
systol
hf
rais
question
whether
serum
concentr
elev
due
gener
increas
express
increas
solubl
activ
repres
redistribut
tissu
serum
higher
rate
releas
cell
may
lead
lower
tissu
level
parallel
increas
serum
activ
latter
case
data
anim
model
suggest
shed
stimul
tumor
necrosi
factora
convertas
moreov
upregul
hf
therefor
cleavag
membran
may
due
upregul
patholog
proteas
relat
proinflammatori
mechan
myocardi
injuri
result
decreas
local
membran
level
increas
tissu
angii
level
decreas
ang
chang
local
concentr
angii
ang
significantli
contribut
remodel
deterior
cardiac
function
figur
consider
part
current
use
biomark
relat
specif
diseas
indirectli
test
solubl
activ
first
time
cardiac
function
improv
chang
drug
therapi
occur
found
solubl
activ
correl
well
improv
cardiac
function
implant
biventricular
pace
devic
crt
particular
improv
ef
crt
correl
neg
serum
activ
figur
improv
cardiac
morpholog
paramet
correl
posit
activ
esd
figur
edd
figur
effort
also
made
correl
solubl
ace
level
cardiovascular
diseas
ace
express
chang
improv
cardiac
function
particular
solubl
ace
concentr
lower
pacemak
implant
healthi
individu
patient
hypertens
preserv
eject
fraction
increas
parallel
improv
cardiac
function
figur
spite
increas
solubl
ace
concentr
solubl
ace
activ
chang
diseas
popul
figur
suggest
effect
therapeut
inhibit
ace
besid
recent
shown
stabil
effect
serum
albumin
ace
activ
regress
analys
ace
concentr
ef
esd
edd
crt
group
show
correl
spite
promis
correl
solubl
ace
concentr
cardiovascular
diseas
figur
moreov
although
ace
express
lower
patient
heart
failur
crt
gener
relationship
disappear
figur
serum
ace
activ
concentr
patient
normal
systol
left
ventricular
function
patient
systol
heart
failur
serum
ace
activ
panel
ace
concentr
panel
b
measur
healthi
peopl
n
fill
bar
patient
preserv
eject
fraction
hypertens
n
grey
bar
patient
sever
heart
failur
hf
crt
cardiac
resynchron
therapi
hf
crt
n
open
bar
statist
analys
biochem
measur
perform
oneway
analysi
varianc
anova
follow
newmankeul
test
multipl
comparison
group
bar
repres
mean
sem
signific
differ
label
asterisk
valu
individu
patient
also
plot
serum
ace
concentr
show
function
eject
fraction
ef
panel
c
end
systol
diamet
esd
panel
e
f
end
diastol
diamet
edd
panel
g
h
plot
fit
linear
regress
valu
good
fit
r
level
correl
p
also
indic
crt
improv
observ
clinic
paramet
data
suggest
ace
express
relat
ultim
clinic
statu
sever
heart
failur
signific
interest
hf
biomark
mani
candid
propos
includ
peptid
enzym
receptor
inflammatori
system
chang
extracellular
matrix
myocyt
oxid
stress
neurohormon
clinic
biomark
test
relat
hf
aim
identifi
possibl
underli
caus
confirm
presenc
absenc
hf
estim
sever
risk
diseas
progress
accord
consensu
document
nation
academi
clinic
biochemistri
us
ideal
biomark
indic
patholog
also
take
element
part
data
suggest
involv
diseas
pathomechan
correl
well
diseas
sever
even
regress
diseas
candid
hf
biomark
base
data
hypothes
redistribut
ace
particular
contribut
pathomechan
hf
found
solubl
ace
concentr
decreas
solubl
concentr
increas
systol
hf
suggest
opposit
chang
tissu
locat
form
enzym
chang
promot
angii
format
tissu
contribut
angii
relat
patholog
therapeut
intervent
lead
improv
cardiac
function
revers
chang
solubl
enzym
concentr
figur
clear
yet
whether
chang
consequ
hf
import
contributor
progress
revers
diseas
nonetheless
latter
support
clinic
effect
ace
inhibitor
drug
manag
hf
inhibit
redistribut
ace
enzym
therefor
repres
new
therapeut
strategi
counterbal
tissu
ra
activ
said
point
hypothesi
limit
lack
direct
measur
tissu
ace
express
may
also
possibl
chang
serum
concentr
ace
repres
chang
express
level
protein
rather
redistribut
issu
need
clarifi
clinic
studi
figur
specif
mcaapk
dnp
hydrolysi
measur
activ
mcaapk
dnp
incub
singl
test
human
serum
sampl
min
presenc
mm
inhibitor
detail
method
complet
inhibit
mcaapk
dnp
hydrolysi
concentr
depend
manner
accord
inhibitori
activ
tiff
figur
hypothet
model
ra
regul
heart
failur
angiotensin
angi
convert
angiotensin
ii
angii
angiotensin
convert
enzym
ace
angii
metabol
angiotensin
ang
angii
bind
activ
type
angii
receptor
ang
bind
activ
ma
receptor
level
tissu
locat
solubl
form
enzym
determin
local
level
angiotensin
peptid
hypothes
signific
redistribut
tissu
solubl
ace
occur
human
heart
failur
chang
revers
upon
improv
cardiac
function
particular
limit
angii
level
healthi
condit
result
low
level
stimul
high
ma
receptor
stimul
condit
benefici
cardiovascular
physiolog
howev
probabl
redistribut
immin
definit
heart
failur
result
activ
increas
circul
blood
decreas
tissu
result
higher
local
ang
ii
level
higher
stimul
lower
ma
receptor
activ
latter
featur
characterist
heart
failur
